Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6164177 | 1.00 | CCNA2 (0.40) | CCNA2CDK2RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL6163634 | 0.85 | CCNA2 (0.39) | CCNA2CDK2RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL6163631 | 0.85 | CCNA2 (0.39) | CCNA2CDK2RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL6164065 | 0.81 | SMN1; SMN2 (0.44) | CCNA2CDK2RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL6163693 | 0.78 | RAB9A (0.41) | CCNA2CDK2RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL6164821 | 0.76 | CYP1A2 (0.43) | CCNA2CDK2RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL6163516 | 0.74 | CCNA2 (0.41) | CCNA2CDK2RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL6164846 | 0.73 | CCNA2 (0.38) | CCNA2CDK2RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6164522 | 0.73 | TACR1 (0.33) | — | |
| SCHEMBL6167319 | 0.72 | RAB9A (0.38) | CCNA2CDK2RAB9ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1177185-B1 | 4, 5, 6, 7-TETRAHYDROINDAZOLE DERIVATIVES AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2005-04-20 | — | — | EP | disclosed |
| US-6716856-B1 | CELL PROLIFERATIVE DISORDERS OR ALZHEIMER'S DISEASE; REDUCED TOXICITY; CDK/CYCLIN KINASE INHIBITORY ACTIVITY | PHARMACIA & TUBJOHN SPA (IT) | 2004-04-06 | — | — | US | disclosed |